People with neuromyelitis optica spectrum disorder (NMOSD) experience faster disability progression with fewer attacks than those with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a related condition, according to a long-term analysis of German registry data. Notably, in all patients, experiencing inflammation in the optic nerve, which transmits signals between…
disability progression
Ofatumumab, a medication approved for multiple sclerosis (MS), effectively prevented relapses and disability progression in a 67-year old woman with neuromyelitis optica spectrum disorder (NMOSD) who failed to respond to rituximab, a Chinese case report described. Both ofatumumab and rituximab — often used off-label in NMOSD — promote the…
People who develop neuromyelitis optica spectrum disorder (NMOSD) later in life may go on to experience worse outcomes than those who have early-onset disease, a study in China has found. Worse outcomes included a higher frequency of inflammation of the thoracic spinal cord during relapses, more brain lesions and…
A low dose of rituximab — infused at 100 mg weekly for three consecutive weeks — was effective at preventing relapses and disability progression in people with neuromyelitis optica spectrum disorder (NMOSD), according to a meta-analysis of five different regimens. Moreover, treatment with rituximab at this low…
Recent Posts
- I may have the dragon fruit of diseases, but let’s not compare apples to oranges
- 17-year-old advocate shares her NMOSD story to raise awareness
- Brain, nerve damage link to relapse, disability in AQP4-related NMOSD
- With NMOSD, my to-do lists now include staying well, as well as staying busy
- Advocates join forces to create, celebrate World NMOSD Awareness Day